

# INVITATION

**FRIDAY**  
**30**  
**SEPT**

**18:00 – 18:45**  
**CET**

**EBMT Transplant Complications Working Party Educational Meeting**

**Therakos Symposium “The role of ECP in the treatment of GvHD in the new world”**

**Mövenpick Hotel Berlin, Germany**

This information is not intended for healthcare professionals based in the US and Canada.

Moderator	<b>Prof Olaf Penack</b> , Charité Universitätsmedizin Berlin, Germany
18:00 – 18:05	<b>Introduction</b> <b>Prof Olaf Penack</b> , Charité Universitätsmedizin Berlin, Germany
18:05 – 18:20	<b>How do I apply current GvHD treatment guidelines</b> <b>Prof Olaf Penack</b> , Charité Universitätsmedizin Berlin, Germany
18:20 – 18:35	<b>How do I use ECP in combinatorial strategies in treating GvHD</b> <b>Prof Zinaida Perić</b> , University Hospital Centre Zagreb, Croatia
18:35 – 18:45	<b>Discussion</b> <b>All Speakers</b>

*ECP: Extracorporeal Photopheresis, GvHD: Graft versus Host Disease*

*All speakers are subject to contract.*

***This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.***

[Privacy policy](#)

Follow the  
Therakos Institute



For more information on THERAKOS ECP Immunomodulation™ please visit [www.therakos.eu](http://www.therakos.eu)  
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.  
© 2022 Mallinckrodt. Item code: EU-2200195. Date of preparation: July 2022.

*Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.*